留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

应中央军委要求,2022年9月起,《药学实践杂志》将更名为《药学实践与服务》,双月刊,正文96页;2023年1月起,拟出版月刊,正文64页,数据库收录情况与原《药学实践杂志》相同。欢迎作者踊跃投稿!

抗骨质疏松治疗药物研究的新进展

贾文斌 刘超 邹燕

贾文斌, 刘超, 邹燕. 抗骨质疏松治疗药物研究的新进展[J]. 药学实践与服务, 2017, 35(6): 490-494,542. doi: 10.3969/j.issn.1006-0111.2017.06.003
引用本文: 贾文斌, 刘超, 邹燕. 抗骨质疏松治疗药物研究的新进展[J]. 药学实践与服务, 2017, 35(6): 490-494,542. doi: 10.3969/j.issn.1006-0111.2017.06.003
JIA Wenbin, LIU Chao, ZOU Yan. Research progress on drugs in osteoporosis therapy[J]. Journal of Pharmaceutical Practice and Service, 2017, 35(6): 490-494,542. doi: 10.3969/j.issn.1006-0111.2017.06.003
Citation: JIA Wenbin, LIU Chao, ZOU Yan. Research progress on drugs in osteoporosis therapy[J]. Journal of Pharmaceutical Practice and Service, 2017, 35(6): 490-494,542. doi: 10.3969/j.issn.1006-0111.2017.06.003

抗骨质疏松治疗药物研究的新进展

doi: 10.3969/j.issn.1006-0111.2017.06.003

Research progress on drugs in osteoporosis therapy

  • 摘要: 骨质疏松是一种常见的全身性骨代谢疾病,主要表现为骨密度与骨量的下降,从而导致继发性骨折。目前,随着其发病率不断增高,骨质疏松已经成为一个世界范围的健康问题和当前医学的研究热点。骨吸收抑制剂主要作用于破骨细胞,通过抑制破骨细胞分化成熟,减少骨吸收;骨形成促进剂主要作用于成骨细胞,激活其骨形成功能,并且有重建骨组织的效应;骨矿化物是防治骨质疏松的基础药物,包括钙剂和维生素D;解偶联剂种类较为单一,代表药物为雷尼酸锶。主要对以上四大类抗骨质疏松药物的研究进展进行介绍。
  • [1] Listed N. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy, March 7-29, 2000:highlights of the conference[J]. South Med J, 2001, 94(6):569-573.
    [2] Lewiecki EM. New targets for intervention in the treatment of postmenopausal osteoporosis[J]. Nat Rev Rheumatol, 2011, 7(11):631-638.
    [3] Riggs BL, Melton LJ Ⅲ. The worldwide problem of osteoporosis:insights afforded by epidemiology[J]. Bone, 1995, 17(5Suppl):505S-511S.
    [4] Kanis JA On behalf of the World Health Organization Scientific Group. Assessment of Osteoporosis at the Primary Health-care Level[M].UK:University of Sheffield, 2008.
    [5] Kanis JA, Johnell O. Requirements for DXA for the management of osteoporosis in Europe[J]. Osteoporosis Int, 2005, 16(3):229-238.
    [6] Burge R, Dawson-Hughes B, Solomon DH, et al. Incidence and economic burden of osteoporosis-related fractures in the United States,2005-2025[J]. J Bone Miner Res,2007, 22(3):465-475.
    [7] Cosman F, de Beur SJ, LeBoff MS, et al. Clinician's guide to prevention and treatment of osteoporosis[J]. Osteoporos Int, 2014, 25(10):2359-2381.
    [8] Rivadeneira F, Mäkitie O. Osteoporosis and bone mass disorders:from gene pathways to treatments[J]. Trends Endocrinol Metab, 2016, 27(5):262-281.
    [9] Seeman E, Delmas PD. Bone quality-the material and structural basis of bone strength and fragility[J]. New Engl J Med, 2008, 26(1):1-8.
    [10] Mafi Golchin M, Heidari L, Ghaderian SM, et al. Osteoporosis:a silent disease with complex genetic contribution[J]. Yi chuan xue bao, 2016, 43(2):49-61.
    [11] Szabo CM, Martin MB, Oldfield E. An investigation of bone resorption and Dictyostelium discoideum growth inhibition by bisphosphonate drugs[J]. J Med Chem, 2002, 45(14):2894-2903.
    [12] Lazar A, Pacurar M, Campian RS. Bisphosphonates in bone diseases treatment[J]. Rev Chimie -Bucharest, 2017, 68(2):246-249.
    [13] Stute P, Birkhäuser M. Selektive Östrogenrezep-tormodulatoren (SERM)[J]. Gynäkologische Endokrinologie, 2015, 13(2):126-134.
    [14] Evans MF, Frank J. Clinical practice guidelines for the diagnosis and management of osteoporosis[J]. Can Fam Physician, 1997, 43(8):635.
    [15] Abdelazim IA, Faza MA, Ayash HM. Effects of Raloxifene hydrochloride on bone mineral density and serum lipids in Kuwaiti postmenopausal women with osteoporosis[J]. Arch Osteoporos, 2015, 4(1):1-5.
    [16] Inzerillo AM, Zaidi M, Huang CL. Calcitonin:physiological actions and clinical applications[J]. J Pediatr Endocr Metab, 2004, 17(7):931-940.
    [17] Atbinici H, Sipahio lu S, Aksoy N, et al. Effects of salmon calcitonin treatment on serum and synovial fluid bone formation and resorption markers in osteoporosis patients[J]. Acta Orthop Traumatol Turc, 2015, 49(2):160-165.
    [18] 马慧萍,贾正平,葛欣,等.骨质疏松症的药物防治研究现状[J],中国药师, 2004, 7(10):816-818.
    [19] Bhandari KH, Asghar W, Newa M, et al. Evaluation of bone targeting salmon calcitonin analogues in rats developing osteoporosis and adjuvant arthritis[J]. Curr Drug Deliv, 2015, 12(1):98-107.
    [20] Rahnama M, Jastrzebska-Jamrogiewicz I, Jamrogiewicz R, et al. Analysis of the influence of hormone replacement therapy on osteocalcin gene expression in postmenopausal women[J]. Biomed Res Int, 2015, 2015:416929.
    [21] Rossini M, Adami G, Adami S, et al. Safety issues and adverse reactions with osteoporosis management[J]. Expert Opin Drug Saf, 2016, 15(3):321-332.
    [22] U.S. Preventive Services Task Force. Hormone therapy for the prevention of chronic conditions in postmenopausal women:recommendations from the U.S. Preventive Services Task Force[J]. Ann Intern Med, 2005, 142(10):855-860.
    [23] Cranney A, Papaioannou A, Zytaruk N, et al. Parathyroid hormone for the treatment of osteoporosis:a systematic review[J]. CMAJ, 2006, 175(1):52-59.
    [24] Hodsman AB, Bauer DC, Dempster DW, et al. Parathyroid hormone and teriparatide for the treatment of osteoporosis:a review of the evidence and suggested guidelines for its use[J]. Endocr Rev, 2005, 26(5):688-703.
    [爲椵湝朠??????楒?攠瑋?慮汯??椬???乳慨瑩楨潡湲慡氠?伬猠琼敩漾灥潴爠潡獬椼猯?匾漮挠楁敮瑡祬?灳物慳挠瑯楦挠慤污?捬汹椠湴楥捲慩汰?杲畡楴摩敤汥椠湴敲?潡湴?癥楮瑴愠浦楯湲???慴湥摯?扯潲湯敳?桳攠慩汮琠桭孥?嵛???愠瑏畳牴楥瑯慰獯???????????㈱??ㄠ????㈩???戲爱?嬼??崾?刲收杝椠湓獨瑩敲牡??夠???牕慥湤摡椠??????慩湭湯慴瑯愠??渠搼??????慬??? ̄?椠?敲瑥?慴汭??楴???味桰敯?灳潥獳椠瑷楩潴湨?潯普?獥琭牷潥湥瑫楬畹洠?牥慲湩数污慲瑡整?楤湥?瑴潨摥慲祡?獹?浦慯湲愠杯敳浴敥湯瑰?潲景?潩獳瑛敊潝瀮漠牏潳獴楥獯孰?嵲??传獉瑮整漬瀠漲爰漱猶??渲琷??日〩???‵祝????????????????扭牭?孲??嵯??攮甠湏楳整牥?偰???剳潩畳砺????即敯敺浵慭湡?????楳?敳琠?慥汲??楡???呩桤敥?敊晝昮攠捎瑡獴?潒晥?猠瑒牨潥湵瑭楡畴浯?爬愠渲攰氱愷琬攠?漳渨?琩栺攵?爲椮猼止?漾晛′瘸敝爠瑔敡扳牨慪汩?普爠慁捈琠畊牲攬?楇湡?睥潬洠敒湆?眠楔瑥桲?灰潡獲瑡浴敩湤潥灛慨畵獭慡汮?潐獔瑈攠漨瀱漭爳漴猩楝猺嬲?崵??乥??湳朠汯????数摥???のっ?????ぴ?????????????扦牥?孹?は嵦?側慨祥攠牤????呦牯敲愠瑴浨敥渠瑴?潥晡?灭潥獮瑴?浯敦渠潯灳慴略獯慰汯?潯獳瑩敳潛灊潝爮漠獊椠獂?扮祥?獍瑩牮潥湲琠楒略浳?爠愲渰攰氶愬琠攲?椨渳?攺瘳攵爴礭搳愶礵?瀼牢慲挾瑛椲挹敝??啩??…猣琲申搳礻嬠?崬???汲楤湩??硃瀬?偌桩慯牵洠慁挬漠氼? ̄?ぴㄠ?????????????????扢物?孩??崠??戠摦畬汵??慩橤敥攠摩?匠???潴桭慥浮敯摰?乵??卬漠敷汯慭楥浮愺湣??买??呡桴敩?略猠敳?潵晤?搠敢汥瑴慷?瑥潮挠潳瑯牤楩敵湭漠汦?慵湯摲?汤潥瘠慡獮瑤愠瑤楩湳?晤潩牵?愠湭瑯楮?潦獬瑵敯潲灯潰牨潯瑳楰捨?瑴桥攭牣慡灬祣孩?嵭???楲晢敯?卡捴楥????ㄠ??????????????扉牮?嬬?㈱崹??愬椠‵??″堩町′???圲由″????椾?攳琰?愠汓??楲???吠桍攬?晕略湤捡琠楓漬渠慓汵?浩敭捯桴慯渠楔猬洠?潩显?獴椠浡癬愼猯瑩愾琮椠湔?楥湡?敭硥灮整爠楲浥敳湰瑯慮汳?潳猠瑷敩潴灨漠牯潮獣楥猭孷?嵥?????潥湲敩??楲湡整物??攠瑴慨扥???べㄠ????????????????扛牊?嬮??嵳??畯????坳攠楉?奴??′倰攱渶本?????椰?攺琳‰愵氷??椰????獢瑲愾扛氳椱獝栠浐敥湲瑥?潲晡?慁?氬甠捃楨晩敢牡愠獆教?愠獤獥愠祌?扭慡猠敃摯?獴捩牮敨敯渠楍湡杴?獥祲獡琠敍浓?映漼物 ̄摥整琠敡捬琼椯湩朾?攠獅瑦牦潥杣整湳?牯敦挠敦灬瑵潯牲?慤来漠湯楮猠瑩獮?極湬?灮氠慳湩瑧?敡硬瑩牮慧挠瑡獮孤?嵢???漠湭敥???は???????????????????扺牥?嬠??嵴?婛桊慝渮朠?儠??兡楣湥???坥???敥?圠???楬?攠琲‰愱氷??椳????漰甭洱愴父椮渼獢?显牛漳洲?挠滖榌摃椬甠洭?济漮渠滣椢攧犨槅?慛湍摝?琠栗斬椺犺?慫渟瓺楈漾猬琠攲漰瀰漳爬漠琶椳挰?愷挱琶椮瘼楢瑲社孛?崳??偂汯慬湬瑡慮??敍摊???ひづ?????????ㄠ??????扯牵?孤??嵥?婰桲慥湳杣?兩奢??兣楡湬??偵???畲愠湶杩??????楄?敳瑵?慰汬??楥???匠瑴畯搠祴?潥湡?攠景晲攠捰瑲獥?潥普?琠潯瑳慴汥?捰潯畲浯慳物楳渿敛獊?昮爠潃浬?瑭桡散?晥牲畩楣琬猠′漰昱‵?渠椱搸椨畳浵?浰潬渲温椺攲爲椭″漱渮?潢獲琾敛漳瀴潝爠潏獳楴獥?楰湯?潯癳慩牳椠敡据瑤漠浢楯穮敥搠?物慮瑥獲孡?崠???桥楡湳?倠桡慳牳浯慣捩????????????????ㄠて??ㄠつ???扮牯?孩??嵡??愠潴??偡??婥桮整渠杯?夠买??六楡湲??偯???楯?敯瑲?慳汩??楊????畨物据甠汊椠杇潥?潥牲挠桐楲潡楣摴攬猠?‰愰?琬爠愵搨椸琩椺漴渵愵氭??样椮渼敢獲放?洳攵摝椠捂楲湩慮汣?灴氠慍測琠??灭牢敩癮攠湊琬猠?扲潩湮散?汴漠獍猬?椼湩 ̄潥癴愠牡楬攼振瑩漾洮椠穔敨摥?牲慯瑬獥嬠?嵦???慴瑡畭物楮琠慄猠??㈠はび???????????????き??扵牲?孴??崬??愰?堵儬??娰栨攳温机愳′???″娲栮愼湢杲 ̄奛???椠?敡瑰?慤汩??楴????湵瑬楯潳猠瑅攬漠灗潥牬潬瑳椠捇?映汓慨癥潡渠潂椬搠猼?显牥潴洠?偬漼搯潩挾愮爠灍楥畴浡?灡潮摡潬捹慳牥灳甠浯学?嵴??偲桡祰瑩潥捳栠敦浯楲猠瑰牯祳??敥瑮瑯???び???????????????金?Ⅷ:Meta-analysis of the efficacy of vitamin D treatment in preventing osteoporosis in postmenopausal women[J]. Endocr Rev, 2002, 23(4):560-569.
    [25] Francis RM, Aspray TJ, Bow
  • [1] 杨媛媛, 安晓强, 许佳捷, 江键, 梁媛媛.  正极性驻极体联合5-氟尿嘧啶对瘢痕成纤维细胞生长抑制的协同作用 . 药学实践与服务, 2024, 42(6): 244-247. doi: 10.12206/j.issn.2097-2024.202310027
    [2] 刘丽艳, 余小翠, 孙传铎.  纳武利尤单抗治疗非小细胞肺癌有效性及安全性的Meta分析 . 药学实践与服务, 2024, 42(): 1-6. doi: 10.12206/j.issn.2097-2024.202310044
    [3] 丁华敏, 郭羽晨, 秦春霞, 宋志兵, 孙莉莉.  消风止痒颗粒通过降低白三烯水平对小鼠特应性皮炎急性瘙痒的治疗作用研究 . 药学实践与服务, 2024, 42(5): 211-216. doi: 10.12206/j.issn.2097-2024.202306031
    [4] 唐淑慧, 凤美娟, 薛智霞, 鲁桂华.  帕博利珠单抗治疗所致免疫相关不良反应与中医体质的相关性研究 . 药学实践与服务, 2024, 42(5): 217-222. doi: 10.12206/j.issn.2097-2024.202311029
    [5] 景凯, 杨慈荣, 张圳, 臧艺蓓, 刘霞.  黄芪甲苷衍生物治疗慢性心力衰竭小鼠的药效评价及作用机制研究 . 药学实践与服务, 2024, 42(5): 190-197. doi: 10.12206/j.issn.2097-2024.202310004
    [6] 张晶晶, 索丽娜, 郑兆红.  89例细菌性肝脓肿的临床特征及抗感染治疗分析 . 药学实践与服务, 2024, 42(6): 267-272. doi: 10.12206/j.issn.2097-2024.202302039
    [7] 张艺昕, 关欣怡, 王博宁, 闻俊, 洪战英.  二氢吡啶类钙离子拮抗药物手性分析及其立体选择性药动学研究进展 . 药学实践与服务, 2024, 42(8): 1-6. doi: 10.12206/j.issn.2097-2024.202308062
    [8] 夏哲炜, 曾垣烨, 朱海菲, 李育, 陈啸飞.  核磁共振磷谱法测定磷酸氢钙咀嚼片中药物含量 . 药学实践与服务, 2024, 42(): 1-4. doi: 10.12206/j.issn.2097-2024.202404063
    [9] 马兹芬, 许维恒, 金煜翔, 薛磊.  食管癌的靶向治疗与免疫治疗研究进展 . 药学实践与服务, 2024, 42(6): 231-237. doi: 10.12206/j.issn.2097-2024.202306008
    [10] 王耀振, 徐灿, 吕顺莉, 田泾, 张东炜.  钾离子竞争性酸阻滞剂的药学特征研究进展 . 药学实践与服务, 2024, 42(7): 278-284. doi: 10.12206/j.issn.2097-2024.202306040
    [11] 张元林, 宋凯, 孙蕊, 舒飞, 舒丽芯, 杨樟卫.  基于真实世界数据的药物利用研究综述 . 药学实践与服务, 2024, 42(6): 238-243. doi: 10.12206/j.issn.2097-2024.202312010
    [12] 宋雨桐, 夏德润, 顾珩, 唐少文, 易洪刚, 沃红梅.  帕博利珠单抗与铂类化疗方案在晚期非小细胞肺癌一线治疗中的药物经济学评价 . 药学实践与服务, 2024, 42(7): 1-7. doi: 10.12206/j.issn.2097-2024.202303023
  • 加载中
计量
  • 文章访问数:  2919
  • HTML全文浏览量:  279
  • PDF下载量:  898
  • 被引次数: 0
出版历程
  • 收稿日期:  2017-08-24
  • 修回日期:  2017-10-16

抗骨质疏松治疗药物研究的新进展

doi: 10.3969/j.issn.1006-0111.2017.06.003

摘要: 骨质疏松是一种常见的全身性骨代谢疾病,主要表现为骨密度与骨量的下降,从而导致继发性骨折。目前,随着其发病率不断增高,骨质疏松已经成为一个世界范围的健康问题和当前医学的研究热点。骨吸收抑制剂主要作用于破骨细胞,通过抑制破骨细胞分化成熟,减少骨吸收;骨形成促进剂主要作用于成骨细胞,激活其骨形成功能,并且有重建骨组织的效应;骨矿化物是防治骨质疏松的基础药物,包括钙剂和维生素D;解偶联剂种类较为单一,代表药物为雷尼酸锶。主要对以上四大类抗骨质疏松药物的研究进展进行介绍。

English Abstract

贾文斌, 刘超, 邹燕. 抗骨质疏松治疗药物研究的新进展[J]. 药学实践与服务, 2017, 35(6): 490-494,542. doi: 10.3969/j.issn.1006-0111.2017.06.003
引用本文: 贾文斌, 刘超, 邹燕. 抗骨质疏松治疗药物研究的新进展[J]. 药学实践与服务, 2017, 35(6): 490-494,542. doi: 10.3969/j.issn.1006-0111.2017.06.003
JIA Wenbin, LIU Chao, ZOU Yan. Research progress on drugs in osteoporosis therapy[J]. Journal of Pharmaceutical Practice and Service, 2017, 35(6): 490-494,542. doi: 10.3969/j.issn.1006-0111.2017.06.003
Citation: JIA Wenbin, LIU Chao, ZOU Yan. Research progress on drugs in osteoporosis therapy[J]. Journal of Pharmaceutical Practice and Service, 2017, 35(6): 490-494,542. doi: 10.3969/j.issn.1006-0111.2017.06.003
参考文献 (25)

目录

    /

    返回文章
    返回